Skip to main content
PMC home page
Springer logoLink to Springer
. 2015 Mar 25;24(7):3107–3116. doi: 10.1007/s00044-015-1364-2

Synthesis and anticancer activity of thiosubstituted purines

Alicja Kowalska 1,✉, Małgorzata Latocha 2, Krystian Pluta 1
PMCID: PMC4491105  PMID: 26167104

Abstract

New thiopurines with the propargylthio, pyrrolidinobutynylthio, sulfenamide, and sulfonamide groups in the pyrimidine ring were synthesized. The anticancer activity of these compounds and previously obtained 2- or 6-substituted azathioprine analogs and dialkylaminoalkylthiopurines were tested in vitro against three cell lines: glioblastoma SNB-19, melanoma C-32, and human ductal breast epithelial tumor T47D. 2-Chloro-7-methyl-6-pyrrolidinobutynylthiopurine (5b) was the most potent compound against SBN-19 and C-32 cell lines with the activity similar to cisplatin (EC50 = 5.00 and 7.58 μg/ml, respectively). The dialkylaminoalkylthio derivatives (4b, 4c, 4e, and 4f) showed good activity against SBN-19 cell line (EC50 < 10 μg/ml). The azathioprine analogs (2a, 2b, and 3a) were more active than azathioprine against SBN-19 and C-32 cell lines. The sulfenamide and sulfonamide derivatives of purine were very weak active against tested cell lines. All studied thiopurines were less toxic than cisplatin.

Electronic supplementary material

The online version of this article (doi:10.1007/s00044-015-1364-2) contains supplementary material, which is available to authorized users.

Keywords: Azathioprine analogs, Dialkylaminoalkylthiopurines, Purinesulfenamides, Purinesulfonamides, Anticancer activity

Introduction

The sulfur-containing purines: 6-mercaptopurine, 6-thioguanine, and azathioprine, have been considered as important and effective drugs used in cancer chemotherapy, for immunosuppression in kidney or heart transplantation and autoimmune diseases (Steurer et al., 2006; Hawwa et al., 2008; Relling et al., 2013; Rao et al., 2013). 6-Mercaptopurine is widely used as an antileukemic agent in the lymphoproliferative disorders, including lymphoma, childhood acute lymphoblastic leukemia, and other neoplastic conditions (Hawwa et al., 2008; Prima et al., 2013; Miron et al., 2009). Azathioprine, but also 6-mercaptopurine exert immunosuppressive effects and are the treatments of choice for severe chronic inflammatory diseases such as rheumatoid arthritis, ulcerative colitis, Crohn’s disease, inflammatory bowel diseases, systemic lupus erythematosus, and multiple sclerosis (Aldinucci et al., 2010; Colombel et al., 2010; Daehn and Karran, 2009). Various pharmacological effects of synthetic thiopurines including antiviral, antibacterial, antitumor, and antifungal activity (Lech-Maranda et al., 2006; Rao et al., 2013) were developed for treatment of patients with infections of human immunodeficiency virus (HIV) and infections caused by herpes and hepatitis virus (Rao et al., 2013; Schow et al., 1997; Chang-Hyun et al., 2001).

However, the use of thiopurines is limited by their toxicities, which include hepatotoxicity, myelosuppression, pancreatitis, and allergic reactions (Prima et al., 2013). For this reason, many thiopurine derivatives and analogs have been synthesized for evaluation of their biological activities and reduced toxicity. Recently, 9-substituted derivatives of 6-(t-butoxycarbamylaminohexyl)thiopurine were obtained which showed moderate antibacterial activity (Rao et al., 2013); a series of 6-mercaptopurine analogs with 1,2,3-triazole or steroid rings exhibited promising antimalarial and antileishmanial activities (Corrales et al., 2011); and biologically active 6-allyldithiopurine and its riboside inhibited cell proliferation and induced apoptosis (Miron et al., 2009).

Heterocyclic sulfonamides are used as carbonic anhydrase inhibitors, antibacterial, anti-inflammatory, analgesic, hypoglycemic, antifungal, and antiviral agent (Joseph et al., 2010; Guzel et al., 2009; Azab et al., 2013; El-Sayed et al., 2011; Veisi et al., 2011). It is known that aryl and heteroaryl sulfonamides may act as antitumor agents through perturbation of cell cycle in the G1 phase, distribution of microtubule assembly, or angiogenesis inhibition. They reverse the effect of tumor acidification, consequently inhibit the growth of cancer cell, and suppress tumor invasion mediated by the carbonic anhydrase active side (Zn2+) and so inhibit the catalytic ability of this enzyme (El-Sayed et al., 2011). Indisulam (E7070) is a novel sulfonamide anticancer agent currently in phase II clinical development for the treatment of several types of cancer. It was shown to act as a nanomolar inhibitor of carbonic anhydrase isoform IX (Sławiński et al., 2013; Mirian et al., 2011).

The sulfamoyl group has been extensively utilized as an activity-modifying substituent in many different classes of drugs. The synthesis of 2-substituted 7- or 9-methylpurines containing a sulfanilamide group at the positions 2, 6, or 8 of the purine ring with moderate antibacterial activity was reported by the reaction of chloropurines with sodium sulfanilamide (Beaman et al., 1966). Structural modification of the amino group at C-6 atom of adenosine leads to selective A1 receptor agonists, while modification at C-2 atom confers high potency and selectivity on A2A receptors. The synthesis of N-9- and 6-amino monosulfonyladenine and disulfonyladenine derivatives and its sulfonylated nucleoside with high potency and selectivity on A1 and A2A receptor agonists has been described (Zinic et al., 2001). A number of 6-sulfenamide, sulfinamide, and sulfonamide derivatives of 6-mercaptopurine, 6-thioguanine, and related ribonucleosides have been synthesized and evaluated for antileukemic activity in mice (Revankar et al., 1990). It is quite interesting that a subtle change to an oxidized sulfur atom in the form of sulfonamide resulted in a new group of purine derivatives possessing significant antitumor properties. Majority of the tested compounds exhibited very significant anti-L1210 cell activity (Revankar et al., 1990; Robins et al., 1991).

Oligonucleotides containing 1-alkynyl-6-thiopurine or 6-thioguanine bases demonstrate potent antiviral activity in several assays, including the human immunodeficiency virus reverse transcriptase enzyme assay (Broom et al., 1997). The purine derivatives possessing the alkynyl groups at position 6 are cytokinin analogs with profound plant growth-stimulating effect and have attracted considerable interest as potential anticancer compounds. All 6-phenylacetylenes and certain enyne of the purine are highly toxic against K-562 cells and exhibit cytotoxic activity against a human chronic myelogenous leukemia cell line comparable to well-known anticancer drugs (6-mercaptopurine and fludarabine) (Brathe et al., 2003). Many adenine and adenosine derivatives with 2-, 6-, or 8-alkynyl substituents are selective adenosine subtypes A1, A2A, A2B, and A3 receptor antagonists. 2-Alkynyl-8-aryl adenine derivatives bear methyl or an amide moiety at the position 9, as A2B receptor antagonists have hypoglycemic activity and may be used as antidiabetic agents (Harada et al., 2001). Stimulating A2A receptor by 2-adenosine propargyl phenyl ether composition resulted in vasodilating activity and potential of using in coronary artery disease (Zablocki et al., 2001). Introduction of alkynyl chains on C-8 atom of adenosine led to very selective antagonists of the A3 receptor (Volpini et al., 2001). Some 2-alkynyl and 2,(6-amino)dialkynyl adenosine derivatives show high affinity and different degrees of selectivity for A1, A2A, and A3 receptor (Volpini et al., 2001).

Our previous research demonstrated the effective synthesis of thiosubstituted purines such as 2- or 6-substituted azathioprine analogs (Kowalska and Pluta, 2008; Kowalska et al., 2009) and dialkylaminoalkylthiopurines (Kowalska and Pluta, 2012). The aim of this study was to elaborate synthesis of new thiopurines with the propargylthio, pyrrolidinobutynylthio, sulfenamide, and sulfonamide groups in the pyrimidine ring, to examine anticancer activity of not only those compounds but also previously synthesized thiopurines and to discuss the structure–activity relationship.

Result and discussion

Chemistry

All thiosubstituted 7-methylpurines were obtained from 2-substituted 7-methylpurine-6-thiones 1a–c and 7-methylpurine-2,6-dithiones 1d. Purinyl sulfides 2–4 with the pharmacophoric 1-methyl-4-nitroimidazol-5-yl and dialkylaminoalkyl groups in positions 2 and 6 were obtained according to the procedures published previously (Kowalska and Pluta, 2008; Kowalska et al., 2009; Kowalska and Pluta, 2012). The alkynylthio derivatives 5 were obtained from 2-chloro derivative 1a and propargyl bromide and further via Mannich reaction with pyrrolidine (Scheme 1).

Scheme 1.

Scheme 1

Open in a new tab

Synthesis of 2- or 6-substituted azathioprine analogs 2, 3, dialkylaminoalkylthiopurines 4, propargylthio- and pyrrolidinobutynylthiopurines 5

The traditional and general method for preparing sulfonamides is based on reaction of sulfonyl chloride with ammonia or amines. The aryl sulfonyl chlorides may be obtained from thiols, sulfides, thioacetals, or thiocarbamines by oxidative chlorination with chlorine gas in aqueous acid (Veisi et al., 2011; Mirian et al., 2011; Ashfaq et al., 2013; Narasaiah et al., 2012; Rehman et al., 2012). 2-Chloro-7-methyl-6-purinethione 1a was chosen as a model compound to prepare S-benzylthiopurine 6. It is known that azinesulfonyl chlorides with the chlorosulfonyl group in aza-activated positions readily lose sulfur dioxide to form chloroazines (Beaman and Robins, 1961; Beaman, 1963; Revankar et al., 1990).

Two-step synthesis of purinesulfonamide 8 via oxidation and chlorination of sulfide 6 with chlorine in acetic acid and subsequent transformation of sulfonyl chloride 7 with ammonia, diethylamine, or aniline failed. In this case, the highly instable chlorosulfonyl group lost sulfur dioxide, and resulted chloropurine reacted with ammonia and amines to give 2-chloro-6-amine derivatives 9a–c with 71–86 % yield (Scheme 2).

Scheme 2.

Scheme 2

Open in a new tab

Synthesis of amine 9, sulfenamide 10, and sulfonamide 8 derivatives of purines

Therefore, the sulfonamide compounds were obtained from purinethione via amination and oxidation. The procedure of S-amination of azinethiones with chloramine solution has been widely used in the preparation of purine-, pyridine-, pyrimidine-, and benzothiazolesulfenamides (Revankar et al., 1990; Robins et al., 1991; Hurley and Robinson, 1965; Schoenwald et al., 1984). For 2-Substituted 7-methyl-6-purinethiones 1a–c, S-amination with a chloramine solution at 0 °C to sulfenamide 10a–c in 85–92.5 % yield was carried out. In the case of purinedithione 1d, two products were obtained: disubstituted compound as the main product, purine-2,6-disulfenamide 10e (66 % yield) and purine-6-sulfenamide 10d (17.5 % yield). Treatment of sulfenamides 10 with 4 molar equivalent of 3-chloroperoxybenzoic acid (MCPBA) at room temperature in ethanol gave purinesulfonamides 8a–d in 66–79 % yield. Lesser equivalents of MCPBA led to sulfenamides (Revankar et al., 1990).

The structure of all new compounds was determined by the spectral data analysis: 1H and 13C NMR, EI, CI or FAB MS, and HR MS. 1H NMR spectra of new compounds revealed H-8, NCH3 proton signals, and protons from C-2 (OCH3, SCH3) and C-6 (CH2C6H5, NH2, N(C2H5)2, NHC6H5, SCH2CCH, SCH2CCCH2NC4H8, SNH2, SO2NH2) substituents. 13C NMR spectra showed primary, secondary, tertiary, and quaternary carbon signals. In order to assign all of these signals, 2D NMR techniques (HSQC—the primary, secondary, and tertiary carbon atoms connected with the hydrogen atoms and HMBC—the primary, tertiary, and quaternary carbon atoms connected with the hydrogen atoms via two and mainly three bonds) for selected compounds (5a, 10e) were used. For compounds 5a, in the HSQC spectrum the H-8 proton at 8.59 ppm correlated with the signal at 151.09 ppm (C-8), the SCH2 proton at 4.22 ppm correlated with the signal at 18.09 ppm (C, SCH2), and the proton at 4.04 ppm (NCH3) correlated with the signal at 34.84 ppm (C, NCH3). The HMBC spectrum revealed correlation via three bonds between the H-8 proton at 8.59 ppm and the carbon signals at 34.84 ppm (C, NCH3), at 123.16 ppm (C-5), and at 160.52 ppm (C-4). The proton signal at 4.22 ppm (H, SCH2) correlated with the signals of carbon atoms via two bonds at 79.55 ppm (C, CCH) and via three bonds at 74.67 ppm (C, CH) and at 153.99 ppm (C-6). The proton signal at 4.04 ppm (H, NCH3) correlated via three bonds with the signals at 123.16 ppm (C-5) and at 151.09 ppm (C-8). The proton–carbon correlation was presented in Scheme 3.

Scheme 3.

Scheme 3

Open in a new tab

2D NMR experiments for compound 5a

Anticancer activity

For the biological tests, 20 thiopurines of five types were selected:

  1. the azathioprine analogs containing the methylnitroimidazolylthio group in position 2 (compounds 2a, 2b), in position 6 (3a–c), and in both positions (3d),

  2. the dialkylaminoalkylthio derivatives containing that substituent with an open-chain amine group in positions 6 (4a, 4b), 2 and 6 (4c, 4d) and with a cyclic amine group (pyrrolidine, piperidine, and morpholine) in positions 2 and 6 (4e–g),

  3. the alkynylthio derivatives containing the propynylthio (5a) and pyrrolidinobutynylthio (5b) groups,

  4. the sulfenamide derivative (10a),

  5. the sulfonamide derivatives with that group in positions 6 (8a–c), and 2 and 6 (8d).

The anticancer activity of the obtained compounds was investigated in vitro using cultured glioblastoma SNB-19, melanoma C-32, and human ductal breast epithelial tumor T47D cell lines. Normal human fibroblasts (HFF-1) were used as a control, and azathioprine and cisplatin as reference drugs. Table 1 contains the activity of thiopurines as the EC50 values.

Table 1.

Antiproliferative activity of thiopurines

Compound Antiproliferative activity EC50 (μg/ml)
SBN-19 C-32 T47-D HFF-1
2a 17.92 21.77 41.11 >50
2b 33.26 35.33 49.60 >50
3a 30.38 12.79 >50 34.93
3b >50 >50 >50 >50
3c >50 >50 48.63 >50
3d >50 >50 >50 >50
4a 28.77 22.47 41.27 >50
4b 8.45 >50 >50 >50
4c 9.82 33.55 24.00 40.00
4d 36.28 >50 >50 >50
4e 7.95 27.05 38.40 35.41
4f 9.18 21.80 32.25 45.50
4g >50 >50 >50 >50
5a 30.95 35.35 44.30 48.95
5b 5.00 7.58 46.00 43.12
8a >50 >50 >50 >50
8b 35.02 >50 >50 >50
8c >50 >50 >50 >50
8d >50 >50 >50 >50
10a >50 >50 >50 >50
Azathioprine 37.20 35.62 39.00 55.88
Cisplatin 4.45 6.28 8.79 30.00
Open in a new tab

The most active was 2-chloro-7-methyl-6-pyrrolidinobutynylthiopurine (5b) with the EC50 values of 5.00 and 7.58 μg/ml against SNB-19 and C-32 cell lines, comparable to the cisplatin effect. This compound exhibited good selectivity and low toxicity, being weak active against T47D cell line and normal fibroblasts HFF-1. The introduction of the pyrrolidine ring to the alkynyl chain enhanced the activity (compound 5b vs. 5a).

Good activity against SNB-19 cell line was observed for the dialkylaminoalkylthio derivatives (4b, 4c, 4e, and 4f) with the EC50 values below 10 μg/ml. The compounds with the ethyl chain were more active than those with the propyl chain. The most active was compound 4e with the two pyrrolidinoethylthio groups. The activity against other cell lines was lesser as well as their toxicity.

The azathioprine analogs with the imidazolylthio group in position 2 were more active than those with that group in position 6 with an exception of compound (3a) which exhibited good activity against C-32 cell line. The most active azathioprine analogs (2a, 3a) possessed the chlorine atom in position 2 or 6. Both compounds were more active than azathioprine (against first two cell lines) and compounds containing the methoxyl and thioalkyl groups (2b, 3b, 3c). Compound 3d with two imidazolylthio groups turned out to be unexpectedly inactive. In our opinion, such an effect was the result of the unusual spatial arrangement of those groups directed to N-1 atom with the donor–acceptor interaction between the imidazole rings, as it was observed in X-ray analysis of the monocrystal 3d (Kowalska et al., 2009).

The sulfenamide and sulfonamide derivatives are very weak active or inactive. The glioblastoma SNB-19 was most sensitive and breast tumor T47D least sensitive cell line for thiopurines. All studied compounds were less toxic than cisplatin.

Conclusion

In search for novel thiopurine derivatives, we described synthesis of 2-chloro-6-alkynylthio-7-methylpurines 5a, 5b from 2-chloro derivative and propargyl bromide and further via Mannich reaction with pyrrolidine. Other types of thiopurines bearing the sulfenamide 10a–e and sulfonamide 8a–d groups were obtained through S-amination of purinethiones 1a–d and oxidation with 3-chloroperoxybenzoic acid.

New thiopurines 5, 8, and 10, previously synthesized azathioprine analogs 2 and 3, and dialkylaminoalkylthiopurines 4 were investigated as antitumor agents. The most potent compound against SBN-19 and C-32 cell lines was 2-chloro-7-methyl-6-pyrrolidinobutynylthiopurine 5b with the activity similar to cisplatin. The dialkylaminoalkylthio derivatives 4b, 4c, 4e, and 4f showed good activity against SBN-19 cell line. The azathioprine analogs 2a, 2b, and 3a were more active than azathioprine against SBN-19 and C-32 cell lines. The sulfenamide and sulfonamide derivatives of thiopurine were very weak active against tested cell lines. All studied thiopurines were less toxic than cisplatin.

Experimental

6-Substituted derivatives of 7-methyl-2-(1-methyl-4-nitroimidazol-5-ylthio)purines 2a–b were prepared from 7-methyl-2,6-di(1-methyl-4-nitroimidazol-5-ylthio)purine 3d exploiting different reactivity of the imidazolylthio groups toward nucleophilic reagents (Kowalska et al., 2009). 2-Substituted derivatives of 7-methyl-6-(1-methyl-4-nitroimidazol-5-ylthio)purines 3a–d were obtained in the reaction of 6-purinethiones with 5-chloro-1-methyl-4-nitroimidazole in 70 % ethanol (Kowalska and Pluta, 2008). 2-Substituted 6-(dialkylaminoalkylthio) 4a–b and 2,6-bis(dialkylaminoalkylthio) derivatives 4c–g were obtained via the direct S-dialkylamination of the appropriate purinethiones (Kowalska and Pluta, 2012). All commercially available organic solvents and reagents were from Sigma-Aldrich and Chempur and were used without further purification.

The melting points were determined in open capillary tubes on a Boetius melting point apparatus and were uncorrected. 1H NMR spectra were recorded on a Bruker AVANS 300 spectrometer operating at 300 MHz and 75 MHz for 1H and 13C nuclei, respectively, in deuterochloroform and dimethyl sulphoxide-d 6 with tetramethylsilane as internal standard. Shifts were given in ppm, coupling constant (J) values were presented in hertz (Hz), and the abbreviations were as follows: s (singlet), d (doublet), t (triplet), and m (multiplet). Electron impact (EI MS), chemical ionization (CI MS), fast atom bombardment (FAB MS), and high-resolution (HR MS) (in the m-nitrobenzyl alcohol and glycerol matrix) mass spectra were run on a Finnigan MAT 95 spectrometer at 70 eV. The reactions were monitored by thin-layer chromatography (TLC) using aluminum sheets coated with silica gel 60F254 (Merck) and chloroform–ethanol (9:1) as the solvents. Purity of the synthesized compounds was confirmed by TLC in the same way. Spots were detected by their absorption under UV light (λ = 254 nm), and the chromatograms were further visualized by iodine vapor. Column chromatography separations were carried out with Merck Kieselgel 60 or aluminum oxide 90 (Merck) using a mixture of chloroform–ethanol (99:1, v/v) as an eluent.

Synthesis of 2-chloro-6-(prop-2-ynylthio)-7-methylpurine5a

Propargyl bromide (0.17 g, 1.44 mmol) was added to a solution generated from the reaction of 2-chloro-7-methyl-6-thiopurine (0.2 g, 1 mmol) with t-BuOK (0.16 g, 1.44 mmol) in 10 ml of DMF at room temperature for 0.5 h. The reaction mixture was stirred for an additional 24 h at room temperature and then added to 25 ml of water. The resulted solid was filtered off and washed with water to give compound 5a. It was obtained as a pale yellow solid (0.22 g, 92 %); mp 183–184 °C (EtOH); 1H NMR (DMSO-d6), δ: 3.26 (t, J = 2.2 Hz, 1H, CH), 4.04 (s, 3H, NCH3), 4.22 (d, J = 2.2 Hz, 2H, SCH2), 8.59 (s, 1H, H-8); 13C NMR (DMSO-d6), δ: 18.09 (CH2, SCH2CCH), 34.84 (CH3, NCH3), 74.67 (CH, SCH2CCH), 79.55 (C, SCH2CCH), 123.00 (C, C-5), 151.09 (CH, C-8), 152.28 (C, C-2), 153.99 (C, C-6), 160.52 (C, C-4); HSQC NMR, δ: 8.59 (H-8) correlated with 151.09 (C-8), 4.22 (H, SCH2) correlated with 18.09 (C, SCH2), 4.04 (H, NCH3) correlated with 34.84 (C, NCH3); HMBC NMR, δ: 8.59 (H-8) correlated with 34.84 (C, NCH3), 123.00 (C-5), and 160.52 (C-4), 4.22 (H, SCH2) correlated with 79.55 (C, CCH), 74.67 (C, CH), and 153.99 (C-6), 4.04 (H, NCH3) correlated with 123.00 (C-5) and 151.09 (C-8); EIMS m/z 238 [M]+ (34.5), 240 [M+2] (12), 203 [M-Cl] (39), 133 [M-Cl, -SCH2CCH] (55), 39 [CH2CCH] (100); HREIMS m/z [M]+ calcd. for C9H7ClN4S 238.0079, found 238.0076.

Synthesis of 2-chloro-6-(4-N-pyrrolidinylbut-2-ynylthio)-7-methylpurine5b

To a mixture of propargyl derivative 5a (0.24 g, 1 mmol) and paraformaldehyde (0.06 g, 2 mmol) in 5 ml of dry dioxane, pyrrolidine (0.14 g, 2 mmol) and CuCl (0.01 g) were added. The reaction mixture was stirred at temperature 70 °C for 2 h. After cooling, the resulting solid was filtered off and purified by column chromatography (silica gel, CHCl3, CHCl3–EtOH, 99:1 v/v) to give compound 5b. It was obtained as a pale yellow solid (0.31 g, 96 %); mp 129–130 °C (EtOH); 1H NMR (CDCl3), δ: 2.13 (m, 8H, 4CH2), 3.12 (t, J = 2.2 Hz, 2H, SCH2), 3.62 (t, J = 2.2 Hz, 2H, CCH2), 4.19 (s, 3H, NCH3), 8.25 (s, 1H, H-8); 13C NMR (DMSO-d6), δ: 18.77 (CH2, SCH2CC), 23.68 (2CH2), 34.86 (CH3, NCH3), 42.58 (CH2, CCH2), 51.86 (2CH2, NCH2), 79.15 (C, SCH2CC), 80.01 (C, SCH2CC), 123.16 (C, C-5), 151.08 (CH, C-8), 152.35 (C, C-2), 154.24 (C, C-6), 160.50 (C, C-4); CIMS m/z 322 [M+1]+ (6.5), 324 [M+1+2] (2.5), 167 [M+1-SCH2CCCH2NC4H8] (9.5), 72 [C4H8NH2]+ (100); HRFABMS m/z [M+H]+ calcd. for C14H17ClN5S 322.0893 found 322.0893.

Synthesis of 2-chloro-6-benzylthio-7-methylpurine6

2-Chloro-6-benzylthio-7-methylpurine 6 was prepared from 2-chloro-7-methyl-6-purinethione 1a (0.2 g, 1 mmol) by alkylation with benzyl chloride (0.25 g, 2 mmol) at room temperature in 4 % aqueous KOH solution (5 ml). After 30 min, the crude product was precipitated, filtered off, washed with water, and crystallized from benzene. It was obtained as a pale yellow solid (0.265 g, 91.5 %); mp 131–132 °C (benzene); 1H NMR (CDCl3), δ: 4.07, (s, 3H, NCH3), 4.64 (s, 2H, CH2), 7.38 (m, 5Harom), 7.98 (s, 1H, H-8); 13C NMR (DMSO-d6), δ: 33.39 (CH2, SCH2), 34.84 (CH3, NCH3), 122.72 (C, C-5), 127.98 (CH, p-CH), 128.99 (2CH, m-CH), 129.84 (2CH, o-CH), 137.12 (C, CCH2), 150.79 (CH, C-8), 152.26 (C, C-2), 155.46 (C, C-6), 160.33 (C, C-4); EIMS m/z 290 [M]+ (100), 292 [M+2] (28.5), 199 [M-C6H5CH2] + (87); HREIMS m/z [M+] calcd. for C13H11ClN4S 290.0392 found 290.0385.

Chlorination and amination of 2-chloro-6-benzylthio-7-methylpurine 6

The chlorinolysis was carried out by passing chlorine gas into a stirred mixture composed of 2-chloro-6-benzylthio-7-methylpurine 6 (0.29 g, 1 mmol), 3 ml of chloroform, and 3 ml of 80 % acetic acid cooled at 5 °C. The passage of chlorine gas was continued for 30 min, and then the mixture was poured into 10 ml of ice water. The chloroform layer was separated, and aqueous layer was extracted with chloroform (2 × 5 ml). The chloroform extracts were combined, washed with water, dried over anhydrous sodium sulfate, and evaporated in vacuo to give an oil residue. In order to remove benzyl acetate and benzyl chloride, the residue was triturated with ice-cold dry ether and the ether layer was separated. The mixture of obtained oil (0.26 g, 1 mmol), and 25 % aqueous ammonia (2.5 ml) or diethylamine (0.22 g, 3 mmol) in 10 % NaOH solution or aniline (0.19 g, 2 mmol) in 2.5 ml of benzene was stirred at 40–45 °C for 2–6 h. The resulted solid was filtered off (in the case of the reaction with ammonia, the excess of ammonia was removed in vacuo and the residue was diluted with water up to volume 2.5 ml) to give compounds 9a–c. Products were purified by a column chromatography (aluminum oxide, CHCl3–EtOH, 99:1 v/v) to give:

2-Chloro-6-amine-7-methylpurine9a

was obtained as a white solid (0.15 g, 82 %); mp 248–249 °C (EtOH), lit. mp 250 °C (Adams and Whitmore, 1945); 1H NMR (DMSO-d6), δ: 3.97 (s, 3H, NCH3), 7.46 (s, 2H, NH2), 8.20 (s, 1H, H-8); 13C NMR (DMSO-d6), δ: 34.29 (CH3, NCH3), 111.12 (C, C-5), 147.27 (CH, C-8), 153.03 (C, C-2), 153.17 (C, C-6), 161.50 (C, C-4); EIMS m/z 183 [M]+ (100), 185 [M+2] (29); HREIMS m/z [M]+ calcd. for C6H6ClN5 183.0311 found 183.0307.

2-Chloro-6-diethylamine-7-methylpurine9b

was obtained as a white solid (0.20 g, 84 %); mp 106–107 °C (EtOH), lit. mp 107 °C (Adams and Whitmore, 1945); 1H NMR (DMSO-d6), δ: 1.17 (t, J = 7.7 Hz, 6H, 2 × CH 3CH2N), 3.52 (q, J = 7.7 Hz, 4H, 2 × CH3 CH 2N), 3 0.94 (s, 3H, NCH3), 8.37 (s, 1H, H-8); 13C NMR (DMSO-d6), δ: 12.93 (2CH3, NCH2CH3), 35.63 (CH3, NCH3), 44.32 (2CH2, NCH2CH3), 114.45 (C, C-5), 149.30 (CH, C-8), 151.81 (C, C-2), 154.70 (C, C-6), 163.03 (C, C-4); EIMS m/z 239 [M]+ (19), 241 [M+2] (6); 210 [M-C2H5], (100); HREIMS m/z [M]+ calcd. for C10H14ClN5 239.0937 found 239.0935.

2-Chloro-6-phenylamine-7-methylpurine9c

was obtained as a white solid (0.18 g, 69 %); mp 202–203 °C. (EtOH); 1H NMR (CDCl3), δ: 3.96 (s, 3H, NCH3), 6.84 (s, 1H, NH), 7.23 (t, J = 7.20 Hz, 1H, p-C6H5), 7.40 (t, J = 7.20 Hz, 2H, m-C6H5), 7.52 (d, J = 7.20 Hz, 2H, o-C6H5), 7.90 (s, 1H, H-8); 13C NMR (DMSO-d6), δ: 34.63 (CH3, NCH3), 112.40 (C, C-5), 123.17 (2CH, m-CH), 124.61 (CH, p-CH), 129.06 (2CH, o-CH), 138.97 (C, CNH), 148.47 (CH, C-8), 149.75 (C, C-2), 152.29 (C, C-6), 162.07 (C, C-4); FABMS m/z 260 [M+1]+ (100), 262 [M+1+2] (31.5); HREIMS m/z [M]+ calcd. for C12H10ClN5 259.0625 found 259.0626.

General synthesis of 2-substituted 7-methyl-6-purinesulfenamide 10a–e

A solution of commercial NaOCl (14.5 %, 1.7 ml) and 1.7 ml of water was cooled to 0 °C in an ice–NaCl bath. Ammonium hydroxide (25 %, 2 ml) was similarly cooled and added with stirring to the bleach solution. The mixture was stirred at −5  to 0 °C for 15 min and then allowed to cool to 0 °C solution of 2-substituted 7-methyl-6-purinethione 1a–d (2 mmol) in 10 % KOH (5 ml) was dropped. The mixture was stirred in stoppered flask for 30 min at temperature −5  to 0 °C. The reaction mixture was initially clear, light yellow solution, but after 30 min a solid began separating. After allowing the reaction mixture to stand at room temperature for an additional 1 h, the precipitated product was filtered off and washed with a small amount of cold water, followed by cold ethanol to yield purine 6-sulfenamide 10a–c, 10e. The crude products were purified by a column chromatography (silica gel, CHCl3, CHCl3–EtOH, 99:1 v/v). The aqueous filtrate separated after precipitation of product 10e was evaporated to dryness and extracted with absolute ethanol (3 × 5 ml). The ethanolic solvent was evaporated, and the residue was purified by column chromatography (aluminum oxide, CHCl3–EtOH, 10:1 v/v) to give compound 10d.

2-Chloro-7-methyl-6-purinesulfenamide10a

was obtained as a yellow solid (0.35 g, 87.5 %); mp 149–150 °C (EtOH); 1H NMR (DMSO-d6), δ: 3.98 (s, 3H, NCH3), 4.41 (s, 2H, NH2), 8.51 (s, 1H, H-8); 13C NMR (DMSO-d6), δ: 35.13 (CH3, NCH3), 120.85 (C, C-5), 150.41 (CH, C-8), 152.99 (C, C-4), 159.88, 164.43 (C, C-2, and C-6); FABMS m/z 216 [M+1]+ (38), 218 [M+1+2] (12), 185 (100); HREIMS m/z [M]+ calcd. for C6H6ClN5S 215.0032 found 215.0029.

2-Methoxy-7-methyl-6-purinesulfenamide10b

was obtained as a yellow solid (0.39 g, 92.5 %); mp 158–159 °C (EtOH); 1H NMR (DMSO-d6), δ: 3.93 (s, 6H, OCH3, NCH3), 4.20 (s, 2H, NH2), 8.30 (s, 1H, H-8); 13C NMR (DMSO-d6), δ: 34.80 (CH3, NCH3), 54.81 (CH3, OCH3), 117.79 (C, C-5), 148.81 (CH, C-8), 160.55 (C, C-4), 161.72, 162.98 (C, C-2, and C-6); FABMS m/z 212 [M+1]+ (100); HREIMS m/z [M]+ calcd. for C7H9N5OS 211.0527 found 211.0523.

2-Methylthio-7-methyl-6-purinesulfenamide10c

was obtained as a yellow solid (0.385 g, 85 %); mp 164–165 °C (EtOH); 1H NMR (DMSO-d6), δ: 2.57 (s, 3H, SCH3), 3.94 (s, 3H, NCH3), 4.25 (s, 2H, NH2), 8.35 (s, 1H, H-8); 13C NMR (DMSO-d6), δ: 14.32 (CH3, SCH3), 34.86 (CH3, NCH3), 119.06 (C, C-5), 151.57 (CH, C-8), 159.32 (C, C-4), 161.52, 164.01 (C, C-2, and C-6); FABMS m/z 228 [M+1]+ (100); HREIMS m/z [M]+ calcd. for C7H9N5S2 227.0299 found 227.0299.

7-Methyl-6-sulfenamide-2-purinethione10d

was obtained as a yellow solid (0.07 g, 16.5 %); mp 254–256 °C (EtOH); 1H NMR (DMSO-d6), δ: 4.20(s, 3H, NCH3), 4.37 (s, 2H, NH2), 8.18 (s, 1H, H-8), 10.83 (s, 1H, NH); 13C NMR (DMSO-d6), δ: 34.68 (CH3, NCH3), 121.30 (C, C-5), 147.96 (CH, C-8), 157.40 (C, C-4), 169.22, 173.95 (C, C-2, and C-6); FABMS m/z 214 [M+1] (100); HREIMS m/z [M]+ calcd. for C6H7N5S2 213.0143 found 213.0141.

7-Methyl-2,6-purinedisulfenamide10e

was obtained as a yellow solid (0.315 g, 69 %); mp 185–186 °C (EtOH); 1H NMR (DMSO-d6), δ: 3.94(s, 3H, NCH3), 4.03 (s, 2H, NH2), 4.18 (s, 2H, NH2), 8.35 (s, 1H, H-8); 13C NMR (DMSO-d6), δ: 34.82(CH3, NCH3), 119.09 (C, C-5), 148.72 (CH, C-8), 159.45 (C, C-4), 161.26, 169.60 (C-2 and C-6); HSQC NMR, δ: 8.35 (H-8) correlated with 148.72 (C-8), 3.94 (H, NCH3) correlated with 34.82 (C, NCH3); HMBC NMR, δ: 8.35 (H-8) correlated with 34.82 (C, NCH3), 119.09 (C-5), and 159.45 (C-4), 3.94 (H, NCH3) correlated with 119.09 (C-5) and with 148.72 (C-8); FABMS m/z 229 [M+1] (100); HREIMS m/z [M]+ calcd. for C6H8N6S2 228.0252 found 228.0255.

General synthesis of 2-substituted 7-methyl-6-purinesulfonamide 8a–c, 8e

A solution of 3-chloroperbenzoic acid (MCPBA) (77 %, 0.86 g, 4 mmol) in 10 ml of ethanol was added dropwise for 10 min to a solution of sulfonamides 10a–c and 10e (1 mmol) in 79 ml of absolute ethanol. The mixture was stirred at room temperature for 1.5 h, and a precipitated solid was filtered off to give crude products 8a–c and 8e. The ethanolic filtrate was evaporated to dryness and extracted with ether to remove 3-chlorobenzoic acid. The solid residue together with crude product was purified by a column chromatography (aluminum oxide, CHCl3, CHCl3–EtOH, 9:1 v/v) to give also compounds 8a–c, 8e.

2-Chloro-7-methyl-6-purinesulfonamide8a

was obtained as a white solid (0.18 g, 73 %); mp 174–175 °C (EtOH); 1H NMR (DMSO-d6), δ: 4.07 (s, 3H, NCH3), 6.91 (s, 2H, NH2), 8.82 (s, 1H, H-8); 13C NMR (DMSO-d6), δ: 36.46 (CH3, NCH3), 121.55 (C, C-5), 151.93 (CH, C-8), 153.88 (C, C-4), 160.39, 164.62 (C, C-2, and C-6); EIMS m/z 247 [M]+ (1.5), 249 [M+2] (0.5); 183 [M-SO2] (14), 168 [M-SO2NH2] (100); HREIMS m/z [M]+ calcd. for C6H6ClN5O2S 246.9930 found 246.9927.

2-Methoxy-7-methyl-6-purinesulfonamide8b

was obtained as a white solid (0.185 g, 76 %); mp 203–204 °C. (EtOH); 1H NMR (DMSO-d6), δ: 3.88 (s, 3H, OCH3), 4.04 (s, 3H, NCH3), 7.99 (s, 2H, NH2), 8.70 (s, 1H, H-8); 13C NMR (DMSO-d6), δ: 35.86 (CH3, NCH3), 55.59 (CH3, OCH3), 117.32 (C, C-5), 133.80 (CH, C-8), 153.60 (C, C-4), 157.55, 166.54 (C, C-2, and C-6); EIMS m/z 243 [M]+ (26), 180 [M-SO2] (55.5), 162 [M-SO2NH2] (8), 148 (100); HREIMS m/z [M]+ calcd. for C7H9N5O3S 243.0426 found 243.0419.

2-Methylthio-7-methyl-6-purinesulfonamide8c

was obtained as a white solid (0.17 g, 66 %); mp 198–199 °C (EtOH); 1H NMR (DMSO-d6), δ: 2.56 (s, 3H, SCH3), 4.03 (s, 3H, NCH3), 7.86 (s, 2H, NH2), 8.75 (s, 1H, H-8); 13C NMR (DMSO-d6), δ: 15.59 (CH3, SCH3), 34.04 (CH3, NCH3), 116.45 (C, C-5), 129.28 (CH, C-8), 133.20 (C, C-4), 147.01, 166.54 (C, C-2, and C-6); CIMS m/z 260 [M+1] (22), 196 [M+1-SO2] (64), 180 (M+1-SO2NH2] (100); HREIMS m/z [M]+ calcd. for C7H9N5O2S2 259.0198 found 259.0195.

7-Methyl-2,6-purinedisulfonamide8d

was obtained as a white solid (0.23 g, 79 %); mp 214–215 °C (EtOH); 1H NMR (DMSO-d6), δ: 4.17(s, 3H, NCH3), 7.01 (s, 2H, NH2), 7.69 (s, 2H, NH2), 8.97 (s, 1H, H-8); 13C NMR (DMSO-d6), δ: 36.30 (CH3, NCH3), 122.52 (C, C-5), 154.76 (CH, C-8), 158.11 (C, C-4), 159.98, 162.99 (C, C-2, and C-6); EIMS m/z 292 [M]+ (9), 229 (M-SO2] (7), 149 [M-SO2 NH2] (22), 57 (100); HREIMS m/z [M]+ calcd. for C6H8N6O4S2 292.0048 found 292.0044.

Antiproliferative assay in vitro

Cell culture

Compounds were evaluated for their anticancer activity using three cultured cell lines: SNB-19 (human glioblastoma, DSMZ—German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany), C-32 (human amelanotic melanoma, ATCC—American Type Culture Collection, Manassas, VA, USA), T47D (human ductal breast epithelial tumor cell line, ATCC, Manassas, VA, USA), and HFF-1 (human fibroblast cell line, ATCC, Manassas, VA, USA). The cultured cells were kept at 37 °C and 5 % CO2. The cells were seeded (1 × 104 cells/well/100 μl DMEM supplemented with 10 % FCS and streptomycin and penicillin) using 96-well plates (Corning).

Proliferation

In recent years, tetrazolium salts have been described which can be used for the measurement of cell proliferation and viability. The tetrazolium salts are cleaved to formazan by cellular enzymes. An expansion in the number of viable cells results in an increase in the overall activity of mitochondrial dehydrogenases in the sample. This augmentation in enzyme activity leads to an increase in the amount of formazan dye formed, which directly correlates with the number of metabolically active cells in the culture. The formazan dye produced by metabolically active cells is quantified by a scanning ELISA reader by measuring the absorbance of the dye solution at appropriate wavelengths (λ = 420–480 nm with a reference wavelength λ = 600 nm).

WST-1 assay

Antiproliferative effect of compounds was determined using the Cell Proliferation Reagent WST-1 assay (Roche Diagnostics, Mannheim, Germany). After exposure to tested compounds (at concentrations between 0 and 100 μg/ml) for 72 h, cells were incubated with WST-1 (10 μl) for 1 h, and the absorbance of the samples against a background control was read at 450 nm using with a reference wavelength λ = 600 nm a microplate reader. Results are expressed as means of at least two independent experiments performed in triplicate.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 5021 kb) (4.9MB, pdf)

Acknowledgments

The synthesis and the structure elucidation are supported by the Medical University of Silesia (Grant KNW-1-004/K/4/0).

References

  1. Adams RR, Whitmore FC. Heterocyclic basic compounds. Dialkylaminoalkylaminopurines. J Am Chem Soc. 1945;67:1271–1273. doi: 10.1021/ja01224a016. [DOI] [Google Scholar]
  2. Aldinucci A, Biagioli T, Manuelli C, Repice AM, Massacesi L, Ballerini C. Modulating dendritic cells (DC) from immunogenic to tolerogenic responses. J Neuroimmunol. 2010;218:28–35. doi: 10.1016/j.jneuroim.2009.11.001. [DOI] [PubMed] [Google Scholar]
  3. Ashfaq M, Shah SSA, Najjam T, Shaheen S, Riviera G. Synthetic routes of sulfonamide derivatives; a brief review. Mini Rev Org Chem. 2013;10:160–170. doi: 10.2174/1570193X11310020005. [DOI] [Google Scholar]
  4. Azab ME, Youssef MM, El-Bordany EA. Synthesis and antibacterial evaluation of novel heterocyclic compounds containing a sulfonamide moiety. Molecules. 2013;18:832–844. doi: 10.3390/molecules18010832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Beaman AG. Heterocyclic nitrogen compounds containing sulfonyl fluoride groups and method of producing some. USA Patent. 1963;3(074):948. [Google Scholar]
  6. Beaman AG, Robins RK. Potential purine antagonists. Synthesis and reactions of some purinesulfonyl fluorides. J Am Chem Soc. 1961;83:4038–4044. doi: 10.1021/ja01480a021. [DOI] [Google Scholar]
  7. Beaman AG, Tantz W, Duschinsky R, Grunberg E. Purine sulfonamides. J Med Chem. 1966;9:373–378. doi: 10.1021/jm00321a027. [DOI] [PubMed] [Google Scholar]
  8. Brathe A, Gundersen LL, Nissen-Meyer J, Rise F, Spilsberg B. Cytotoxic activity of 6-alkynyl- and 6-alkenylpurines. Bioorg Med Chem Lett. 2003;13:877–880. doi: 10.1016/S0960-894X(03)00011-8. [DOI] [PubMed] [Google Scholar]
  9. Broom AD, Gall AA, Meyer RB (1997) Oligonucleotides containing n-methyl thiolated bases having antiviral activity. US Patent 5652359 A
  10. Chang-Hyun O, Hee-Kwon K, Su-Chul L, Changsok O, Boem-Seok Y, Seok RJ. Synthesis and biological propertis of C-2, C-8, N-9 substituted 6-(3-chloroanilino)-purine derivatives cyclin—dependent kinase inhibitors. Arch Pharm Med Chem. 2001;334:345–350. doi: 10.1002/1521-4184(200112)334:11&#x0003c;345::AID-ARDP345&#x0003e;3.0.CO;2-1. [DOI] [PubMed] [Google Scholar]
  11. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D’Haens G, Diamond RH, Broussard DL, Tang KI, van der Wande CJ, Rutgeerts P. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–1395. doi: 10.1056/NEJMoa0904492. [DOI] [PubMed] [Google Scholar]
  12. Corrales RCNR, de Souza NB, Pinheiro LS, Abramo C, Coimbra ES, da Silva AD. Thiopurine derivatives containing triazole and steroid: synthesis, antimalarial and antileishmanial activities. Biomed Pharmacother. 2011;65:198–203. doi: 10.1016/j.biopha.2010.10.013. [DOI] [PubMed] [Google Scholar]
  13. Daehn EI, Karran P. Immune effector cells produce lethal DNA damage in cells treated with a thiopurine. Cancer Res. 2009;69:2393–2399. doi: 10.1158/0008-5472.CAN-08-4264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. El-Sayed NS, El-Bendary ER, El-Ashry SM, El-Kerdawy MM. Synthesis and antitumor activity of new sulfonamide derivatives of thiadiazolo[3,2-α]pyrimidines. Eur J Med Chem. 2011;46:3714–3720. doi: 10.1016/j.ejmech.2011.05.037. [DOI] [PubMed] [Google Scholar]
  15. Guzel O, Innocenti A, Scozzafava A, Salman A, Supuran CT. Carbonic anhydrase inhibitors. Phenacetyl-, pyridylacetyl- and thienylacetyl substituted aromatic sulfonamides act as potent and selective isoform VII inhibitors. Bioorg Med Chem Lett. 2009;19:3170–3173. doi: 10.1016/j.bmcl.2009.04.123. [DOI] [PubMed] [Google Scholar]
  16. Harada H, Asano O, Kawata T, Inoue T, Horizoe T, Yasuda N, Nagata K, Murakami M, Nagaoka J, Kobayashi S, Tanaka I, Abe S. 2-Alkynyl-8-aryladenines possessing an amide moiety: their synthesis and structure–activity relationships of effects on hepatic glucose production induced via agonism of the A2B adenosine receptor. Bioorg Med Chem. 2001;9:2709–2726. doi: 10.1016/S0968-0896(01)00201-2. [DOI] [PubMed] [Google Scholar]
  17. Hawwa AF, Collier PS, Millership JS, McCarthy A, Dempsey S, Cairns C, McElnay JC. Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. Br J Clin Pharmacol. 2008;66:826–837. doi: 10.1111/j.1365-2125.2008.03281.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hurley TJ, Robinson MA. The reaction of chloramine with mercaptopyrimidine and mercaptopyrimidine derivatives. J Med Chem. 1965;8:888–889. doi: 10.1021/jm00330a048. [DOI] [PubMed] [Google Scholar]
  19. Joseph P, Turtant F, Ouahrani-Bettache S, Montero JL, Nishimori I, Minakuchi T, Vullo D, Scozzafava A, Kohler S, Winum JY, Supuran CT. Cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Brucelle suis. J Med Chem. 2010;53:2277–2285. doi: 10.1021/jm901855h. [DOI] [PubMed] [Google Scholar]
  20. Kowalska A, Pluta K. Synthesis of the azathioprine analogs. Heterocycles. 2008;75:555–569. doi: 10.3987/COM-07-11232. [DOI] [Google Scholar]
  21. Kowalska A, Pluta K. Synthesis of 2- and 6-(dialkylaminoalkylthio)- and 2,6-bis(dialkylaminoalkylthio)-7-methylpurines. Heterocycles. 2012;85:2473–2483. doi: 10.3987/COM-12-12546. [DOI] [Google Scholar]
  22. Kowalska A, Pluta K, Suwińska K. Synthesis of isomeric analogs of azathioprine. Heterocycles. 2009;78:2455–2466. doi: 10.3987/COM-09-11742. [DOI] [Google Scholar]
  23. Lech-Maranda E, Robak E, Korycka A, Robak T. Pharmacological and clinical studies on purine nucleoside analogs—new anticancer agents. Mini Rev Med Chem. 2006;6:575–581. doi: 10.2174/138955706776876212. [DOI] [PubMed] [Google Scholar]
  24. Mirian M, Zarghi A, Sadeghi S, Tabaraki P, Tavallaee M, Dadrass O, Sadeghi-aliabadi H. Synthesis and cytotoxic evaluation of some novel sulfonamide derivatives against a few human cancer cells. Iran J Pharm Res. 2011;10:741–748. [PMC free article] [PubMed] [Google Scholar]
  25. Miron T, Arditti F, Konstantinovski L, Rabinkov A, Mirelman D, Berrebi A, Wilchek M. Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylmercaptopurines. Eur J Med Chem. 2009;44:541–550. doi: 10.1016/j.ejmech.2008.03.027. [DOI] [PubMed] [Google Scholar]
  26. Narasaiah T, Rao DS, Ramana KV, Adam S, Raju CN. Synthesis of new sulfonamide derivatives of tryptamine and their antimicrobial activity. Der Pharma Chem. 2012;4:1582–1590. [Google Scholar]
  27. Prima FD, Shenoy A, Moses SR, Shabaraya AR. Antitumor activity of mercaptopurine in combination with trikatu and gomutra on 20-methylcholantrene induced carcinogenesis. J App Pharm Sci. 2013;3:20–23. [Google Scholar]
  28. Rao PV, Ravindhranath K, Kumar KR. Antibacterial activity of novel substituted mercaptopurine derivatives. Inst J Pharm Biomed Res. 2013;4:127–131. [Google Scholar]
  29. Rehman A, Afroz S, Abbasi MA, Tanveer W, Khan KM, Ashraf M, Ahmad I, Afzal I, Ambreen N. Synthesis, characterization and biological screening of sulfonamides derived form 2-phenylethylamine. Pak J Pharm Sci. 2012;25:809–814. [PubMed] [Google Scholar]
  30. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Hicks JK, Schwab M, Klein TE. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2013;93:324–325. doi: 10.1038/clpt.2013.4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Revankar GR, Hanna NB, Imamura N, Lewis AF, Larson SB, Finch RA, Avery TL, Robins RK. Synthesis and in vivo antitumor activity of 2-amino-9H-purine-6-sulfenamide, -sulfinamide, and sulfonamide and related purine ribonucleosides. J Med Chem. 1990;33:121–128. doi: 10.1021/jm00163a020. [DOI] [PubMed] [Google Scholar]
  32. Robins RK, Revankar GR, Hanna NB. 6-Sulfenamide, 6-sulfinamide and 6-sulfonamide purines, purine nucleosides, purine nucleotides, pharmaceutical compositions, and processes of making. USA Patent. 1991;5(026):836. [Google Scholar]
  33. Schoenwald RD, Eller MG, Dixon JA, Barfknecht CF. Topical carbonic anhydrase inhibitors. J Med Chem. 1984;27:810–812. doi: 10.1021/jm00372a020. [DOI] [PubMed] [Google Scholar]
  34. Schow SR, Mackman RL, Blum CL, Brooks E, Horsma AG, Joly A, Kerwar SS, Lee G, Shiffman D, Nelson MG, Wang X, Wick MM, Zhang X, Lum RT. Synthesis and activity 2,6,9-trisubstituted purines. Bioorg Med Chem Lett. 1997;7:2697–2702. doi: 10.1016/S0960-894X(97)10076-2. [DOI] [Google Scholar]
  35. Sławiński J, Szafrański K, Vullo D, Supuran CT. Carbonic anhydrase inhibitors. Synthesis of heterocyclic 4-substituted pyridine-3-sulfonamide derivatives and their human cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII. Eur J Med Chem. 2013;69:701–710. doi: 10.1016/j.ejmech.2013.09.027. [DOI] [PubMed] [Google Scholar]
  36. Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R. Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. Cancer Treat Rev. 2006;32:377–389. doi: 10.1016/j.ctrv.2006.05.002. [DOI] [PubMed] [Google Scholar]
  37. Veisi H, Ghorbani-Vaghei R, Mahmoodi J. Poly(N, N′-dichloro-N-ethyl-benzene-1,3-disulfonamide) and N, N, N′, N′-tetrachlorobenzene-1,3-disulfonamide as efficient reagents to direct oxidative conversion of thiols and disulfide to sulfonyl chlorides. Bull Korean Chem Soc. 2011;32:3692–3695. doi: 10.5012/bkcs.2011.32.10.3692. [DOI] [Google Scholar]
  38. Volpini R, Costanzi S, Lambertucci C, Vittori S, Klotz KN, Lorenzen A, Cristalli G. Introduction of alkynyl chains on C-8 of adenosine led to very selective antagonists of the A3 adenosine receptor. Bioorg Med Chem Lett. 2001;11:1931–1934. doi: 10.1016/S0960-894X(01)00347-X. [DOI] [PubMed] [Google Scholar]
  39. Zablocki AJ, Palle VP, Elzein EO, Nudelman G (2001) Propargyl phenyl ether A2A receptor agonists. US Patent 6180615 B1
  40. Zinic B, Krizmanic I, Vikic-Topic D, Srzic D, Zinic M. Synthesis, NMR and MS study of novel N-sulfonylated purine derivatives. Croat Chem Acta. 2001;74:399–414. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary material 1 (PDF 5021 kb) (4.9MB, pdf)

Articles from Medicinal Chemistry Research are provided here courtesy of Springer

RESOURCES